Ganeden’s digestion treatment proves effective

In one double-blind, placebo-controlled study in irritable bowel syndrome (IBS), 57% of the participants noted a significant reduction in abdominal pain and bloating after taking Ganeden’s IBS treatment, Digestive Advantage, for eight weeks.

IBS is a chronic condition of the gastrointestinal tract that is characterized by erratic episodes of abdominal pain, bloating, diarrhea, and constipation. Affecting as many as one in five Americans, IBS can have a substantial impact on patients’ lives and forces many people with IBS to restrict their diets drastically to manage symptoms.

In a second proof-of-concept clinical trial involving patients with Crohn’s disease, an extremely painful disease of the large intestine, patients taking Digestive Advantage noted a 40% reduction in episodes of diarrhea. In fact, four out of five patients who were using prescription medications were able to stop taking their standard medications.

“While our treatments are not cures, they are a natural, clinically proven way to control the symptoms of these two debilitating conditions,” said Andy Lefkowitz, CEO of Ganeden Biotech. “Many patients are finding relief by taking our products alone or in tandem with prescription medications.”